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The hands are commonly involved in RA
Rheumatoid arthritis (RA) is a chronic, auto-immune dis-
order characterised by inflammation primarily in the
joints. The small joints in the hands are typically involved
in RA, with both the 1987 American Rheumatism Asso-
ciation revised criteria for RA classification including
“arthritis of hand joints” as one of the criterion [1] and
the 2010 RA classification criteria awarding more points
for small joint involvement (i.e. themetacarpophalangeal
joints, proximal interphalangeal joints, second to fifth
metatarsophalangeal joints, thumb interphalangeal joints
and wrists) [2].
RA is the most common of the inflammatory arthri-
tides; a study in the UK found the prevalence of RA to be
1.16% in women and 0.44% in men [3]. In Asia, the pre-
valence of RA varies from country to country. In rural
areas, the prevalence of RA is 0.12% in Thailand, 0.2% in
Indonesia, 0.26% in Taiwan, 0.3% in Malaysia, 0.34% in
China, 0.55% in India and 0.7% in Bangladesh [4].
Pathogenesis of joint destruction
Although a specific antigen that triggers off the immune
response in RA has not been convincingly identified, cell-
mediated immune responses (especially from the T cells)
have been shown to be responsible for RA joint inflam-
mation. In an susceptible host (e.g. a person with the
appropriate genetic background), the T cell response
results in the elaboration of T cell cytokines, with resul-
tant recruitment of inflammatory cells, including neutro-
phils, macrophages, B cells and memory T cells. A target
of the inflammatory cells is the synovium which becomes
markedly hyperplastic and infiltrated with mononuclear-
cells. One feature of RA that distinguishes it from other
inflammatory arthropathies is the propensity for the
synovium to become locally invasive at the synovial inter-
face with cartilage and bone. This destructive mass is
called “pannus” and is responsible for the characteristic
marginal erosions observed in RA [5]. Cartilage is further
destroyed in RA by the catabolic effects of cytokines such
as IL-1, IL-6 and tumour necrosis factor-alpha (TNF-a)
and the production of metalloproteinases, which can
degrade extra-cellular matrix/cartilage, causing more
joint damage[5].
Apart from synovitis, inflammation of the adjacent
intertrabecular space (osteitis) also correlates with the
development of radiographic bone erosions.Articular
bone erosion represents localized bone loss (osteolysis),
which results from an imbalance in which bone resorp-
tion by osteoclasts is favoured over bone formation by
osteoblasts [6]. In RA, TNF-a and receptor activated
nuclear factor  ligand (RANKL) are key cytokines med-
iating the activation of the osteoclasts [7].
Studies have shown that erosive disease develops early in
the course of RA in the majority of patients. The rate of
progression is fastest in the first 2 years [8]. Longitudinal
studies have shown that after 2 years approximately 36%
of patients have erosions, 47% by 5 years [9] and 63% by
8 years [10]. If both joint space narrowing and erosions
are considered, up to 70% of patients will show radio-
graphic damage after 3 years [11].
Does treatment prevent erosions?
Treatment for RA must involve suppression of the
immune-mediated inflammatory response, which requires
the use ofdisease-modifying anti-rheumatic drugs
(DMARDs). Methotrexate (MTX) is the anchor synthetic
DMARD.Good control of inflammation/remission (no joint
swelling or tenderness, normal ESR/CRP) will reduce the
rate of progression of erosions [12] and hence joint damage.
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pain and swelling, improving function and reducing the
ESR. However, its efficacy at inducing disease remission
is limited (only in approximately 25% of patients)
andhence less efficacious at reducing radiographic pro-
gression [13]. Biologics are monoclonal antibodies pro-
duced against various inflammatory cytokines such as
TNF-a or IL-6. Compared to MTX, biologics are very
much more effective atinducing disease remission and
hence reducing the progression of joint damage as
assessed by radiographic change scores (e.g. [13-15].
Unfortunately, a major barrier to the widespread use of
biologics is their high cost. In addition, approximately
20% of patients do not achieve adequate disease suppres-
sion with biologic treatment [16]. So, despite the avail-
ability of treatment, many patients with RA remain
undertreatedand thus have continuing joint destruction.
Nonetheless, since the mid-1990s, studies have shown
that the amount of hand surgery in RA patients has been
slowly declining, postulated to improvements in medical
therapy [17,18].
Conclusion
Adequate and early treatmentof RA does reduce the rate
of radiographic progression and hence joint damage.
Although the drugs are available, the most effective
drugs are not widely used due to cost issues. Thus, RA
hand surgery will still be needed in the foreseeable
future.
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